Transgenic mouse capable of over-expressing VE-PTP
The present invention relates generally to a transgenic mouse. In particular, the present invention relates to a transgenic mouse whose genome comprises a TetO-VE-PTP transgene. The present invention also relates to a double transgenic mouse whose genome comprises the transgenes TetO-VE-PTP and Tie2-tTA, which is capable of conditionally over-expressing VE-PTP which is contingent on the presence of doxycycline. The present invention also relates to methods of generating a transgenic mouse whose genome comprises a TetO-VE-PTP and a double transgenic mouse whose genome comprises the transgenes TetO-VE-PTP and Tie2-tTA.
1 . A double transgenic mouse capable of conditionally over-expressing VE-PTP which is contingent on the presence of doxycycline.
2 . The double transgenic mouse of claim 2 , wherein the transgenic mouse is C57BL/6 or C57BL/6×CBA.
3 . A transgenic responder line mouse whose genome comprises a TetO-VE-PTP transgene.
4 . The transgenic responder line mouse of claim 3 , wherein the transgenic responder line mouse is C57BL/6 or C57BL/6×CBA.
5 . A method of producing a transgenic responder line mouse whose genome comprises a TetO-VE-PTP transgene comprising the steps of:
a) introducing a DNA solution comprising TetO-VE-PTP into mouse oocytes;
b) transferring the mouse oocytes to a pseudo-pregnant surrogate female mouse; and
c) allowing the oocytes to develop to term thereby producing a transgenic responder line mouse whose genome comprises a TetO-VE-PTP transgene.
6 . The method of claim 5 , wherein the transgenic responder line mouse is C57BL/6 or C57BL/6×CBA.
7 . A double transgenic mouse whose genome comprises the transgenes TetO-VE-PTP and Tie2-tTA.
8 . The double transgenic mouse of claim 7 , wherein the double transgenic mouse is C57BL/6 or C57BL/6×CBA.
9 . A method of producing a double transgenic mouse comprising: crossing a transgenic mouse responder line comprising TetO-VE-PTP with a transgenic mouse driver line comprising Tie2-tTA.
10 . The method of claim 9 , wherein the double transgenic mouse is C57BL/6 or C57BL/6×CBA.